trending Market Intelligence /marketintelligence/en/news-insights/trending/FWA8Ccc4n2LPQQkBFLqRyA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

BioCryst seeks US FDA approval for swelling disorder pill

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


BioCryst seeks US FDA approval for swelling disorder pill

BioCryst Pharmaceuticals Inc. filed an application with the U.S. Food and Drug Administration for its oral pill berotralstat to prevent severe swelling attacks in patients with a rare genetic disorder.

The Durham, N.C.-based company's new drug application is for berotralstat, or BCX7353, to prevent hereditary angioedema attacks. Hereditary angioedema is a disease characterized by recurrent attacks of severe swelling of the skin and mucous membranes. The most common areas of the body to develop swelling are the limbs, face, intestinal tract and airway.

In May, BioCryst said its oral medicine helped reduce the attack rate in patients enrolled in a late-stage study conducted in the U.S., Canada and Europe.

According to BioCryst CEO Jon Stonehouse, the company is preparing to commercialize the treatment in 2020.